Novartis (NYSE:NVS) shares are in the green in the pre-markets session today after two phase 3 clinical trials showed its Consentyx demonstrated superior efficacy over placebo in symptoms of skin disease hidradenitis suppurativa (HS).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
HS affects about one in 100 people globally causing painful lesions. The company has submitted data from the two trials to European authorities and plans to submit it in the U.S. by the end of the year as well.
The drug showed rapid relief from the ailment as well as a favorable safety profile. Long-term results from these trials are expected in 2023. Additionally, Novartis also aims to expand the drug to 10 indications.
Read full Disclosure